Showing 71 - 80 of 129
We study optimal contracts in a regulator-agent setting with joint production, altruistic and selfish agents, and uneasy outcome measurement. Such a setting represents sectors of activities such as education and health care provision. The agents and the regulator jointly produce an outcome for...
Persistent link: https://www.econbiz.de/10012945490
In theory, health care providers may adapt their professional behavior to the financial incentives driven by their remuneration. Our research question is whether the users of health care services anticipate such a behavior from their general practitioner (GP) and, if they do, what are the...
Persistent link: https://www.econbiz.de/10013024347
This paper analyzes how drug approval procedures influence the incentives of pharmaceutical firms to launch new drugs in the presence of international reference pricing. First, we show that the set of countries in which a firm commercializes a new drug is larger when countries do not approve...
Persistent link: https://www.econbiz.de/10013045987
Some countries allow physicians to balance bill patients, that is, to bill a fee above the one that is negotiated with, and reimbursed by the health authorities. Balance billing is known for restricting access to physicians’ services while supplemental insurance against balance billing amounts...
Persistent link: https://www.econbiz.de/10010858038
This paper analyzes how drug approval procedures influence the incentives of pharmaceutical firms to launch new drugs in the presence of international reference pricing. First, we show that the set of countries in which a firm commercializes a new drug is larger when countries do not approve...
Persistent link: https://www.econbiz.de/10010935046
This paper analyzes how drug approval procedures influence the incentives of pharmaceutical firms to launch new drugs in the presence of international reference pricing. First, we show that the set of countries in which a firm commercializes a new drug is larger when countries do not approve...
Persistent link: https://www.econbiz.de/10010936719
In this paper we investigate the implications of permitting parallel imports ofpharmaceuticals produced by a monopoly, from one country to another. We use a modelwhere countries differ in the patients’ level of co-payment for buying pharmaceuticals, andpatients differ in the utility obtained...
Persistent link: https://www.econbiz.de/10005304476
Persistent link: https://www.econbiz.de/10005204397
The aim of this paper is to compare the role of general practitioners in determining access to specialised and hospitalised health care in two different types of health care systems: Systems where a GP referral is compulsory for specialist/hospitalised attention and systems where this referral...
Persistent link: https://www.econbiz.de/10009292414
External referencing (ER) imposes a price cap for pharmaceuticals based on prices of identical products in foreign countries. Suppose a foreign country (F) negotiates prices with a pharmaceutical firm while a home country (H) can either negotiate independently or implement ER based on the...
Persistent link: https://www.econbiz.de/10014216337